drugset
drugset / Trial / NCT07055386

A Study to Compare the Efficacy and Safety of GZR102 Injection and GZR18 Injection in Type 2 Diabetes Mellitus

NCT07055386 ↗

Phase 2 Active not recruiting 90 enrolled Gan & Lee Pharmaceuticals.
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a multicenter, randomized, open-label, positive controlled efficacy exploration study. To compare the efficacy and safety of once-weekly GZR102 Injection and Bi-Weekly GZR18 Injection in Chinese adult subjects with type 2 diabetes mellitus (T2DM) and inadequate glycemic control on GLP-1 receptor agonists (GLP-1RAs), with or without oral antidiabetic drugs (OADs).

Timeline

Start
2025-08-07
Primary completion
2026-06-28
Completion
2027-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Bofanglutide Protein / enzyme biologic — Subcutaneous
Subject GZR102 Unknown — Subcutaneous

Indications

type 2 diabetes mellitus